Rethinking systemic adjuncts in periodontitis: a single centre acquisition cost comparison of antimicrobial and non-antimicrobial therapies
Open Access
- 18 September 2026
- journal article
- research article
- Published by Springer Nature in British Dental Journal
- p. 1-5
Abstract
Aims To compare National Health Service (NHS) acquisition costs of systemic antimicrobial regimens with emerging non-antimicrobial adjuncts in periodontal therapy and to model potential national financial implications. Methods A secondary acquisition cost comparison analysis was undertaken using three-year prescription data (2021–2024) from a service evaluation at Charles Clifford Dental Hospital. Antibiotic prescriptions were cross-referenced with clinical records to identify those issued for periodontitis. Direct acquisition costs were calculated using Sheffield Teaching Hospitals NHS Foundation Trust pricing. Results Of 643 antibiotic prescriptions, 445 (69.2%) were issued for periodontitis. Azithromycin accounted for 93.5% of periodontal prescriptions, whereas guideline-recommended amoxicillin plus metronidazole (A+M) represented 1.6%. Compared with A+M (£2.81 per course), azithromycin reduced acquisition costs by 55.16%. Non-antimicrobial adjuncts demonstrated substantially greater reductions depending on treatment duration, with metformin 500 mg achieving up to 91.46% reduction. Conclusions Non-antimicrobial systemic adjuncts demonstrate considerable direct cost advantages over traditional antimicrobial regimens. These findings highlight potential economic and antimicrobial stewardship benefits and support the need for formal cost-effectiveness analyses to inform future prescribing guidance.Keywords
This publication has 26 references indexed in Scilit:
- Antibiotic resistance in the microbiota of periodontitis patients: an update of current findingsCritical Reviews in Microbiology, 2023
- Adjunctive probiotics after periodontal debridement versus placebo: a systematic review and meta-analysisActa Odontologica Scandinavica, 2021
- Shifting the paradigm from inhibitors of inflammation to resolvers of inflammation in periodontitisJournal of Periodontology, 2020
- Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018JAMA, 2020
- Oral antibiotic prescribing by NHS dentists in England 2010-2017British Dental Journal, 2019
- Drug repurposing: progress, challenges and recommendationsNature Reviews Drug Discovery, 2018
- High-Dose Atorvastatin Reduces Periodontal InflammationJACC, 2013
- Adjunctive benefits of systemic amoxicillin and metronidazole in non‐surgical treatment of generalized aggressive periodontitis: a randomized placebo‐controlled clinical trialJournal of Clinical Periodontology, 2005
- Antibiotic resistance of subgingival species during and after antibiotic therapyJournal of Clinical Periodontology, 2002
- Anti-Inflammatory Activity of Macrolide AntibioticsThe Journal of Pharmacology and Experimental Therapeutics, 2000